|
G
|
Il6
|
interleukin 6
|
multiple interactions
|
ISO
|
1,2-Dipalmitoylphosphatidylcholine inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL6 protein]
|
CTD |
PMID:19041333 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Prnp
|
prion protein
|
multiple interactions affects folding
|
ISO
|
Copper affects the reaction [1,2-Dipalmitoylphosphatidylcholine affects the folding of PRNP protein modified form]
|
CTD |
PMID:20936829 |
|
NCBI chr 3:139,639,076...139,654,420
Ensembl chr 3:139,630,144...139,658,436
|
|
|
G
|
Fech
|
ferrochelatase
|
affects abundance
|
ISO
|
FECH protein affects the abundance of 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine
|
CTD |
PMID:29906468 |
|
NCBI chr18:60,215,325...60,248,525
Ensembl chr18:60,215,325...60,249,546
|
|
|
G
|
Fech
|
ferrochelatase
|
affects abundance
|
ISO
|
FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine
|
CTD |
PMID:29906468 |
|
NCBI chr18:60,215,325...60,248,525
Ensembl chr18:60,215,325...60,249,546
|
|
|
G
|
Nr5a2
|
nuclear receptor subfamily 5, group A, member 2
|
multiple interactions
|
ISO
|
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of 1-oleoyl lysophosphatidylcholine
|
CTD |
PMID:29515023 |
|
NCBI chr13:50,865,253...50,985,107
Ensembl chr13:50,867,920...50,984,938
|
|
G
|
Smad3
|
SMAD family member 3
|
decreases abundance
|
ISO
|
SMAD3 protein results in decreased abundance of 1-oleoyl lysophosphatidylcholine
|
CTD |
PMID:23034213 |
|
NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324
|
|
|
G
|
Agtr1a
|
angiotensin II receptor, type 1a
|
increases expression
|
ISO
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of AGTR1 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660
|
|
G
|
Alox5
|
arachidonate 5-lipoxygenase
|
increases expression
|
ISO
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of ALOX5 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:151,203,949...151,251,126
|
|
G
|
Ccr2
|
C-C motif chemokine receptor 2
|
increases expression
|
ISO
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CCR2 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:132,611,410...132,620,059
|
|
G
|
Cd68
|
Cd68 molecule
|
increases expression
|
ISO
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CD68 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr10:54,880,562...54,882,441
Ensembl chr10:54,880,563...54,882,540
|
|
G
|
Crp
|
C-reactive protein
|
increases expression
|
ISO
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of CRP mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514
|
|
G
|
Gja1
|
gap junction protein, alpha 1
|
multiple interactions increases phosphorylation
|
EXP
|
AG 1879 inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]; resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]
|
CTD |
PMID:24079413 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689
|
|
G
|
Il1a
|
interleukin 1 alpha
|
increases expression
|
ISO
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1A mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013
|
|
G
|
Il1b
|
interleukin 1 beta
|
increases expression
|
ISO
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of IL1B mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Kcnab2
|
potassium voltage-gated channel subfamily A regulatory beta subunit 2
|
multiple interactions
|
EXP
|
[KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine
|
CTD |
PMID:21296056 |
|
NCBI chr 5:168,182,228...168,270,760
Ensembl chr 5:168,184,613...168,270,760
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
increases phosphorylation multiple interactions
|
EXP
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:24079413 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions increases phosphorylation
|
EXP
|
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:24079413 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Olr1
|
oxidized low density lipoprotein receptor 1
|
increases expression
|
ISO
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of OLR1 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr 4:164,612,460...164,635,082
Ensembl chr 4:164,612,463...164,634,598
|
|
G
|
Ptafr
|
platelet-activating factor receptor
|
affects binding multiple interactions
|
ISO
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine binds to PTAFR protein 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]
|
CTD |
PMID:16386258 |
|
NCBI chr 5:150,049,322...150,079,060
Ensembl chr 5:150,049,460...150,079,408
|
|
G
|
Ptgs1
|
prostaglandin-endoperoxide synthase 1
|
increases expression
|
ISO
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS1 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
increases expression
|
ISO
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of PTGS2 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Sele
|
selectin E
|
increases expression increases secretion
|
ISO
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of SELE mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of SELE protein
|
CTD |
PMID:16386258 |
|
NCBI chr13:78,935,997...78,945,905
Ensembl chr13:78,936,036...78,945,903
|
|
G
|
Src
|
SRC proto-oncogene, non-receptor tyrosine kinase
|
multiple interactions increases phosphorylation
|
EXP
|
resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of SRC protein]
|
CTD |
PMID:24079413 |
|
NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462
|
|
G
|
Timp4
|
TIMP metallopeptidase inhibitor 4
|
increases expression
|
ISO
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TIMP4 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr 4:149,978,667...149,985,350
Ensembl chr 4:149,978,685...149,985,452
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases expression increases secretion
|
ISO
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TNF mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of TNF protein
|
CTD |
PMID:16386258 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
|
G
|
Lipg
|
lipase G, endothelial type
|
increases hydrolysis
|
ISO
|
LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine
|
CTD |
PMID:15953354 |
|
NCBI chr18:70,790,077...70,811,259
Ensembl chr18:70,790,077...70,812,260
|
|
|
G
|
Lipc
|
lipase C, hepatic type
|
multiple interactions
|
ISO
|
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin
|
CTD |
PMID:24777581 |
|
NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:80,390,471...80,516,285
|
|
G
|
Lipg
|
lipase G, endothelial type
|
multiple interactions
|
ISO
|
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of stearoyl alpha-lysolecithin
|
CTD |
PMID:24777581 |
|
NCBI chr18:70,790,077...70,811,259
Ensembl chr18:70,790,077...70,812,260
|
|
|
G
|
Agtr1a
|
angiotensin II receptor, type 1a
|
increases expression
|
ISO
|
Platelet Activating Factor results in increased expression of AGTR1 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660
|
|
G
|
Alox12
|
arachidonate 12-lipoxygenase, 12S type
|
increases expression
|
ISO
|
Platelet Activating Factor results in increased expression of ALOX12 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr10:55,456,923...55,469,239
Ensembl chr10:55,456,928...55,469,199
|
|
G
|
Alox5
|
arachidonate 5-lipoxygenase
|
multiple interactions increases expression
|
ISO
|
[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Platelet Activating Factor] Platelet Activating Factor results in increased expression of ALOX5 mRNA
|
CTD |
PMID:8387780 PMID:10779545 PMID:16386258 |
|
NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:151,203,949...151,251,126
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
multiple interactions increases secretion
|
ISO
|
Foropafant inhibits the reaction [Platelet Activating Factor results in increased secretion of CCL2 protein]
|
CTD |
PMID:15149885 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Ccr2
|
C-C motif chemokine receptor 2
|
increases expression
|
ISO
|
Platelet Activating Factor results in increased expression of CCR2 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:132,611,410...132,620,059
|
|
G
|
Crp
|
C-reactive protein
|
increases expression
|
ISO
|
Platelet Activating Factor results in increased expression of CRP mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514
|
|
G
|
Cx3cr1
|
C-X3-C motif chemokine receptor 1
|
increases expression
|
ISO
|
Platelet Activating Factor results in increased expression of CX3CR1 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr 8:128,661,294...128,679,048
Ensembl chr 8:128,654,833...128,685,983
|
|
G
|
Edn1
|
endothelin 1
|
multiple interactions increases abundance
|
EXP
|
Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]; EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]
|
CTD |
PMID:18205269 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687
|
|
G
|
Ednrb
|
endothelin receptor type B
|
multiple interactions
|
EXP
|
EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]
|
CTD |
PMID:18205269 |
|
NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765
|
|
G
|
Egr1
|
early growth response 1
|
increases expression
|
ISO
|
Platelet Activating Factor results in increased expression of EGR1 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843
|
|
G
|
Gusb
|
glucuronidase, beta
|
multiple interactions
|
EXP
|
[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein; IMMLG5521 inhibits the reaction [[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein]
|
CTD |
PMID:23850278 |
|
NCBI chr12:32,337,281...32,350,838
Ensembl chr12:32,334,075...32,363,024
|
|
G
|
Il1a
|
interleukin 1 alpha
|
increases expression
|
ISO
|
Platelet Activating Factor results in increased expression of IL1A mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013
|
|
G
|
Il1b
|
interleukin 1 beta
|
increases expression increases secretion multiple interactions
|
ISO
|
Platelet Activating Factor results in increased expression of IL1B mRNA Platelet Activating Factor results in increased secretion of IL1B protein [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL1B protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]
|
CTD |
PMID:16386258 PMID:32830409 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions increases secretion
|
ISO
|
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL6 protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]
|
CTD |
PMID:32830409 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Itgam
|
integrin subunit alpha M
|
multiple interactions increases expression
|
ISO
|
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]; Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]
|
CTD |
PMID:9762784 PMID:11116075 |
|
NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:192,089,542...192,139,943
|
|
G
|
Ltb4r
|
leukotriene B4 receptor
|
affects response to substance
|
ISO
|
LTB4R1 protein affects the susceptibility to Platelet Activating Factor
|
CTD |
PMID:10934231 |
|
NCBI chr15:33,233,120...33,235,636
Ensembl chr15:33,232,820...33,235,637
|
|
G
|
Mmp13
|
matrix metallopeptidase 13
|
increases expression
|
ISO
|
Platelet Activating Factor results in increased expression of MMP13 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105
|
|
G
|
Myd88
|
MYD88, innate immune signal transduction adaptor
|
increases expression multiple interactions
|
ISO
|
Platelet Activating Factor results in increased expression of MYD88 protein PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]
|
CTD |
PMID:32830409 |
|
NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230
|
|
G
|
Nceh1
|
neutral cholesterol ester hydrolase 1
|
multiple interactions
|
ISO
|
NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor]
|
CTD |
PMID:18164358 |
|
NCBI chr 2:112,003,677...112,064,274
Ensembl chr 2:112,003,502...112,064,272
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions increases degradation
|
ISO
|
Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Genistein inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; herbimycin inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]
|
CTD |
PMID:10921504 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Olr1
|
oxidized low density lipoprotein receptor 1
|
increases expression
|
ISO
|
Platelet Activating Factor results in increased expression of OLR1 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr 4:164,612,460...164,635,082
Ensembl chr 4:164,612,463...164,634,598
|
|
G
|
Pla2g7
|
phospholipase A2 group VII
|
multiple interactions increases expression
|
ISO
|
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Platelet Activating Factor] results in increased expression of PLA2G7 mRNA; bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PLA2G7 mRNA]
|
CTD |
PMID:21432021 |
|
NCBI chr 9:24,859,491...24,901,747
Ensembl chr 9:24,859,502...24,901,747
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
decreases expression
|
ISO
|
Platelet Activating Factor results in decreased expression of PPARA mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Ptafr
|
platelet-activating factor receptor
|
multiple interactions increases expression increases phosphorylation affects binding
|
ISO EXP
|
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50730 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50739 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; CMI 392 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; MK 287 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; zileuton inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] Platelet Activating Factor results in increased expression of PTAFR mRNA Platelet Activating Factor results in increased phosphorylation of PTAFR protein bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]; Carbon Tetrachloride promotes the reaction [Platelet Activating Factor binds to PTAFR protein]; RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]; TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]
|
CTD |
PMID:9065783 PMID:10447766 PMID:11297424 PMID:11529688 PMID:16386258 PMID:18205269 More...
|
|
NCBI chr 5:150,049,322...150,079,060
Ensembl chr 5:150,049,460...150,079,408
|
|
G
|
Ptgs1
|
prostaglandin-endoperoxide synthase 1
|
increases expression
|
ISO
|
Platelet Activating Factor results in increased expression of PTGS1 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
increases expression
|
ISO
|
Platelet Activating Factor results in increased expression of PTGS2 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Pvt1
|
Pvt1 oncogene
|
increases expression multiple interactions
|
ISO
|
Platelet Activating Factor results in increased expression of PVT1 mRNA [Platelet Activating Factor co-treated with PVT1 mRNA] affects the expression of MIR149 mRNA; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein]
|
CTD |
PMID:32830409 |
|
NCBI chr 7:95,545,916...95,769,306
|
|
G
|
Rgs4
|
regulator of G-protein signaling 4
|
multiple interactions
|
EXP
|
RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]
|
CTD |
PMID:11297424 |
|
NCBI chr13:84,469,593...84,475,884
Ensembl chr13:84,469,593...84,475,884
|
|
G
|
Sele
|
selectin E
|
increases expression
|
ISO
|
Platelet Activating Factor results in increased expression of SELE mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr13:78,935,997...78,945,905
Ensembl chr13:78,936,036...78,945,903
|
|
G
|
Sell
|
selectin L
|
multiple interactions increases secretion
|
ISO
|
Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]
|
CTD |
PMID:9762784 |
|
NCBI chr13:78,950,100...78,969,604
Ensembl chr13:78,950,015...78,969,600
|
|
G
|
Selp
|
selectin P
|
multiple interactions increases expression
|
ISO
|
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of SELP protein]
|
CTD |
PMID:11116075 |
|
NCBI chr13:79,009,379...79,044,994
Ensembl chr13:79,009,475...79,044,987
|
|
G
|
Timp4
|
TIMP metallopeptidase inhibitor 4
|
increases expression
|
ISO
|
Platelet Activating Factor results in increased expression of TIMP4 mRNA
|
CTD |
PMID:16386258 |
|
NCBI chr 4:149,978,667...149,985,350
Ensembl chr 4:149,978,685...149,985,452
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases secretion multiple interactions increases expression
|
ISO EXP
|
Platelet Activating Factor results in increased secretion of TNF protein [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of TNF protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein] TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA] Platelet Activating Factor results in increased expression of TNF mRNA Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]
|
CTD |
PMID:9065783 PMID:10921504 PMID:16386258 PMID:32830409 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases expression
|
EXP
|
platelet-activating factor increases expression of Tnf protein in portal stenosis rat plasma
|
RGD |
PMID:10452877 |
RGD:38508900 |
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
|
G
|
Casp3
|
caspase 3
|
decreases expression
|
ISO
|
Cytidine Diphosphate Choline results in decreased expression of CASP3 protein
|
CTD |
PMID:12443983 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
decreases expression
|
EXP
|
Cytidine Diphosphate Choline results in decreased expression of ICAM1 mRNA
|
CTD |
PMID:16193989 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Nceh1
|
neutral cholesterol ester hydrolase 1
|
multiple interactions
|
ISO
|
NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor]
|
CTD |
PMID:18164358 |
|
NCBI chr 2:112,003,677...112,064,274
Ensembl chr 2:112,003,502...112,064,272
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
decreases expression
|
ISO
|
Cytidine Diphosphate Choline results in decreased expression of PARP1 protein modified form
|
CTD |
PMID:12443983 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Sirt1
|
sirtuin 1
|
increases expression multiple interactions
|
EXP
|
Cytidine Diphosphate Choline results in increased expression of SIRT1 protein Cytidine Diphosphate Choline results in increased expression of and results in increased activity of SIRT1 protein
|
CTD |
PMID:23600725 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000
|
|
|
G
|
Ache
|
acetylcholinesterase
|
decreases activity
|
ISO
|
Echothiophate Iodide results in decreased activity of ACHE protein
|
CTD |
PMID:16978018 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410
|
|
G
|
Alb
|
albumin
|
affects binding
|
ISO
|
Echothiophate Iodide binds to ALB protein
|
CTD |
PMID:15525694 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
G
|
Bche
|
butyrylcholinesterase
|
decreases activity multiple interactions
|
ISO
|
Echothiophate Iodide results in decreased activity of BCHE protein Echothiophate Iodide inhibits the reaction [BCHE protein results in increased hydrolysis of Butyrylthiocholine]
|
CTD |
PMID:7377577 PMID:16213467 PMID:17698511 PMID:21802514 |
|
NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:160,606,288...160,699,760
|
|
G
|
Nceh1
|
neutral cholesterol ester hydrolase 1
|
decreases activity
|
ISO
|
Echothiophate Iodide results in decreased activity of NCEH1 protein
|
CTD |
PMID:16978018 |
|
NCBI chr 2:112,003,677...112,064,274
Ensembl chr 2:112,003,502...112,064,272
|
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
ISO
|
edelfosine inhibits the reaction [Nicotine results in increased phosphorylation of BCL2 protein]; edelfosine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BCL2 protein]; edelfosine promotes the reaction [Cytarabine results in decreased expression of BCL2 protein]
|
CTD |
PMID:9295281 PMID:12421819 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
F2rl1
|
F2R like trypsin receptor 1
|
multiple interactions
|
ISO
|
edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [allyl isothiocyanate results in increased activity of TRPA1 protein]]; edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [cinnamaldehyde results in increased activity of TRPA1 protein]]
|
CTD |
PMID:17571167 |
|
NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:28,507,003...28,519,954
|
|
G
|
Lep
|
leptin
|
multiple interactions
|
ISO
|
edelfosine inhibits the reaction [LEP protein results in increased transport of Calcium]
|
CTD |
PMID:20107083 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661
|
|
G
|
Plcb2
|
phospholipase C, beta 2
|
multiple interactions
|
ISO
|
edelfosine inhibits the reaction [Cytarabine affects the localization of PLCB2 protein]; edelfosine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PLCB2 protein]
|
CTD |
PMID:9295281 |
|
NCBI chr 3:126,134,925...126,158,303
Ensembl chr 3:126,138,736...126,158,221
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
increases expression
|
ISO
|
edelfosine results in increased expression of PTGS2 protein
|
CTD |
PMID:12485854 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Trpa1
|
transient receptor potential cation channel, subfamily A, member 1
|
multiple interactions
|
ISO
|
edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [allyl isothiocyanate results in increased activity of TRPA1 protein]]; edelfosine inhibits the reaction [F2RL1 protein promotes the reaction [cinnamaldehyde results in increased activity of TRPA1 protein]]
|
CTD |
PMID:17571167 |
|
NCBI chr 5:9,163,060...9,217,325
Ensembl chr 5:9,163,060...9,217,325
|
|
|
G
|
Gdpd5
|
glycerophosphodiester phosphodiesterase domain containing 5
|
affects abundance
|
ISO
|
GDPD5 protein affects the abundance of Glycerylphosphorylcholine
|
CTD |
PMID:33617914 |
|
NCBI chr 1:163,091,844...163,173,559
Ensembl chr 1:163,091,833...163,173,559
|
|
G
|
Pnpla6
|
patatin-like phospholipase domain containing 6
|
affects abundance
|
ISO
|
PNPLA6 protein affects the abundance of Glycerylphosphorylcholine
|
CTD |
PMID:36336212 |
|
NCBI chr12:6,372,284...6,401,632
Ensembl chr12:6,372,293...6,401,631
|
|
|
G
|
Bmal1
|
basic helix-loop-helix ARNT like 1
|
affects abundance
|
ISO
|
BMAL1 gene mutant form affects the abundance of Lysophosphatidylcholines
|
CTD |
PMID:27056296 |
|
NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:176,829,305...176,864,739
|
|
G
|
Casp3
|
caspase 3
|
increases expression multiple interactions
|
ISO
|
Lysophosphatidylcholines results in increased expression of CASP3 protein GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of CASP3 protein]
|
CTD |
PMID:34293432 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Cav1
|
caveolin 1
|
multiple interactions increases expression
|
ISO
|
alpha-Tocopherol inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 mRNA]; Quercetin inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 mRNA]; Quercetin inhibits the reaction [Lysophosphatidylcholines results in increased expression of CAV1 protein] Lysophosphatidylcholines results in increased expression of CAV1 mRNA; Lysophosphatidylcholines results in increased expression of CAV1 protein
|
CTD |
PMID:27257344 |
|
NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740
|
|
G
|
Enpp2
|
ectonucleotide pyrophosphatase/phosphodiesterase 2
|
multiple interactions
|
ISO
|
[[Capsaicin results in increased chemical synthesis of Lysophosphatidylcholines] which results in increased secretion of Lysophosphatidylcholines] promotes the reaction [ENPP2 results in increased chemical synthesis of lysophosphatidic acid]; [ENPP2 protein co-treated with Lysophosphatidylcholines] results in increased chemical synthesis of lysophosphatidic acid
|
CTD |
PMID:19014389 |
|
NCBI chr 7:88,092,140...88,214,758
Ensembl chr 7:88,092,140...88,214,957
|
|
G
|
Enpp7
|
ectonucleotide pyrophosphatase/phosphodiesterase 7
|
increases hydrolysis
|
ISO
|
ENPP7 protein results in increased hydrolysis of Lysophosphatidylcholines
|
CTD |
PMID:12885774 |
|
NCBI chr10:104,740,763...104,745,760
Ensembl chr10:104,740,763...104,745,760
|
|
G
|
Fscn1
|
fascin actin-bundling protein 1
|
increases expression
|
ISO
|
Lysophosphatidylcholines results in increased expression of FSCN1 mRNA
|
CTD |
PMID:22102721 |
|
NCBI chr12:16,710,601...16,723,734
Ensembl chr12:16,710,601...16,723,734
|
|
G
|
Gja1
|
gap junction protein, alpha 1
|
increases ubiquitination multiple interactions
|
EXP
|
Lysophosphatidylcholines results in increased ubiquitination of GJA1 protein Lysophosphatidylcholines affects the localization of and results in increased phosphorylation of GJA1 protein; PRKCE affects the reaction [Lysophosphatidylcholines results in increased phosphorylation of GJA1 protein]
|
CTD |
PMID:23973256 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689
|
|
G
|
Gpr4
|
G protein-coupled receptor 4
|
increases expression multiple interactions
|
ISO
|
Lysophosphatidylcholines results in increased expression of GPR4 mRNA; Lysophosphatidylcholines results in increased expression of GPR4 protein GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of CASP3 protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL18 protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL1B protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL33 protein]; GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of NLRP3 protein]
|
CTD |
PMID:34293432 |
|
NCBI chr 1:87,993,398...88,004,568
Ensembl chr 1:87,993,430...88,006,254
|
|
G
|
Hmox1
|
heme oxygenase 1
|
increases expression
|
ISO
|
Lysophosphatidylcholines results in increased expression of HMOX1 mRNA
|
CTD |
PMID:9808084 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
G
|
Icam1
|
intercellular adhesion molecule 1
|
increases expression multiple interactions
|
ISO
|
Lysophosphatidylcholines results in increased expression of ICAM1 mRNA quercetin 3-O-glucuronide inhibits the reaction [Lysophosphatidylcholines results in increased expression of ICAM1 mRNA]; Quercetin inhibits the reaction [Lysophosphatidylcholines results in increased expression of ICAM1 mRNA]
|
CTD |
PMID:27257344 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
G
|
Il18
|
interleukin 18
|
increases expression multiple interactions
|
ISO
|
Lysophosphatidylcholines results in increased expression of IL18 protein GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL18 protein]
|
CTD |
PMID:34293432 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286
|
|
G
|
Il1b
|
interleukin 1 beta
|
increases expression multiple interactions
|
ISO
|
Lysophosphatidylcholines results in increased expression of IL1B protein GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL1B protein]
|
CTD |
PMID:34293432 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il33
|
interleukin 33
|
increases expression multiple interactions
|
ISO
|
Lysophosphatidylcholines results in increased expression of IL33 protein GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of IL33 protein]
|
CTD |
PMID:34293432 |
|
NCBI chr 1:237,115,478...237,149,897
Ensembl chr 1:237,115,572...237,150,901
|
|
G
|
Lama3
|
laminin subunit alpha 3
|
increases expression
|
ISO
|
Lysophosphatidylcholines results in increased expression of LAMA3 mRNA
|
CTD |
PMID:15541073 |
|
NCBI chr18:3,797,898...4,033,021
Ensembl chr18:3,797,939...4,026,449
|
|
G
|
Lamb3
|
laminin subunit beta 3
|
increases expression
|
ISO
|
Lysophosphatidylcholines results in increased expression of LAMB3 mRNA
|
CTD |
PMID:15541073 |
|
NCBI chr13:107,362,514...107,404,081
Ensembl chr13:107,322,526...107,404,081
|
|
G
|
Lamc2
|
laminin subunit gamma 2
|
increases expression
|
ISO
|
Lysophosphatidylcholines results in increased expression of LAMC2 mRNA
|
CTD |
PMID:15541073 |
|
NCBI chr13:67,835,199...67,894,694
Ensembl chr13:67,835,199...67,895,102
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions increases phosphorylation
|
EXP
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:20564508 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions increases phosphorylation
|
EXP
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:20564508 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mfsd2a
|
MFSD2 lysolipid transporter A, lysophospholipid
|
increases transport
|
ISO
|
MFSD2A results in increased transport of Lysophosphatidylcholines
|
CTD |
PMID:26005865 |
|
NCBI chr 5:140,510,933...140,525,828
Ensembl chr 5:140,510,953...140,525,916
|
|
G
|
Nlrp3
|
NLR family, pyrin domain containing 3
|
multiple interactions increases expression
|
ISO
|
GPR4 protein promotes the reaction [Lysophosphatidylcholines results in increased expression of NLRP3 protein]
|
CTD |
PMID:34293432 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions increases expression
|
EXP
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased expression of NOS2 mRNA]; Resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased expression of NOS2 mRNA]
|
CTD |
PMID:20564508 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Nos3
|
nitric oxide synthase 3
|
multiple interactions decreases expression
|
EXP
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in decreased expression of NOS3 mRNA]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in decreased expression of NOS3 mRNA]
|
CTD |
PMID:20564508 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664
|
|
G
|
Nr5a2
|
nuclear receptor subfamily 5, group A, member 2
|
multiple interactions
|
ISO
|
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Lysophosphatidylcholines
|
CTD |
PMID:29515023 |
|
NCBI chr13:50,865,253...50,985,107
Ensembl chr13:50,867,920...50,984,938
|
|
G
|
Pah
|
phenylalanine hydroxylase
|
multiple interactions
|
ISO
|
Lysophosphatidylcholines results in increased activity of [PAH protein binds to PAH protein binds to PAH protein binds to PAH protein]
|
CTD |
PMID:19367645 |
|
NCBI chr 7:23,793,096...23,885,631
Ensembl chr 7:23,792,781...23,885,627
|
|
G
|
Pnpla6
|
patatin-like phospholipase domain containing 6
|
affects abundance
|
ISO
|
PNPLA6 protein affects the abundance of Lysophosphatidylcholines
|
CTD |
PMID:36336212 |
|
NCBI chr12:6,372,284...6,401,632
Ensembl chr12:6,372,293...6,401,631
|
|
G
|
Prkce
|
protein kinase C, epsilon
|
multiple interactions
|
EXP
|
PRKCE affects the reaction [Lysophosphatidylcholines results in increased phosphorylation of GJA1 protein]
|
CTD |
PMID:23973256 |
|
NCBI chr 6:13,718,050...14,204,931
Ensembl chr 6:13,718,050...14,204,288
|
|
G
|
Ptgs1
|
prostaglandin-endoperoxide synthase 1
|
decreases expression multiple interactions
|
EXP
|
Lysophosphatidylcholines results in decreased expression of PTGS1 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in decreased expression of PTGS1 mRNA]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in decreased expression of PTGS1 mRNA]
|
CTD |
PMID:20564508 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990
|
|
G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions increases expression
|
EXP
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lysophosphatidylcholines results in increased expression of PTGS2 mRNA]; resveratrol inhibits the reaction [Lysophosphatidylcholines results in increased expression of PTGS2 mRNA]
|
CTD |
PMID:20564508 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
G
|
Tp53
|
tumor protein p53
|
multiple interactions
|
ISO
|
[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Lysophosphatidylcholines
|
CTD |
PMID:30258081 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Trpc5
|
transient receptor potential cation channel, subfamily C, member 5
|
multiple interactions
|
ISO
|
Lysophosphatidylcholines promotes the reaction [TRPC5 protein results in increased transport of Calcium]; resveratrol inhibits the reaction [Lysophosphatidylcholines promotes the reaction [TRPC5 protein results in increased transport of Calcium]]
|
CTD |
PMID:21127073 |
|
NCBI chr X:112,742,828...113,027,638
Ensembl chr X:112,742,828...113,027,638
|
|
G
|
Vcam1
|
vascular cell adhesion molecule 1
|
increases expression
|
ISO
|
Lysophosphatidylcholines results in increased expression of VCAM1 mRNA
|
CTD |
PMID:27257344 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801
|
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
decreases response to substance multiple interactions
|
ISO
|
ABCB1 protein results in decreased susceptibility to miltefosine miltefosine binds to and results in decreased activity of ABCB1 protein
|
CTD |
PMID:11355955 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Prkca
|
protein kinase C, alpha
|
decreases phosphorylation
|
ISO
|
miltefosine results in decreased phosphorylation of PRKCA protein
|
CTD |
PMID:31265827 |
|
NCBI chr10:93,388,991...93,787,617
Ensembl chr10:93,388,991...93,787,572
|
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
increases secretion
|
ISO
|
ABCB11 protein results in increased secretion of Phosphatidylcholines
|
CTD |
PMID:14570929 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
affects export affects transport
|
ISO
|
ABCB1 protein affects the export of Phosphatidylcholines ABCB1 protein affects the transport of Phosphatidylcholines
|
CTD |
PMID:11147995 PMID:11745043 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
G
|
Abcb4
|
ATP binding cassette subfamily B member 4
|
affects transport affects export
|
ISO
|
ABCB4 protein affects the transport of Phosphatidylcholines ABCB4 protein affects the export of Phosphatidylcholines
|
CTD |
PMID:11745043 PMID:15696852 |
|
NCBI chr 4:26,106,895...26,164,440
|
|
G
|
Acat1
|
acetyl-CoA acetyltransferase 1
|
decreases activity
|
EXP
|
Phosphatidylcholines results in decreased activity of ACAT1 protein
|
CTD |
PMID:12559476 |
|
NCBI chr 8:62,876,003...62,905,080
Ensembl chr 8:62,876,003...62,905,042
|
|
G
|
Adipoq
|
adiponectin, C1Q and collagen domain containing
|
decreases expression
|
ISO
|
Phosphatidylcholines results in decreased expression of ADIPOQ mRNA
|
CTD |
PMID:23911798 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169
|
|
G
|
Ahr
|
aryl hydrocarbon receptor
|
multiple interactions increases abundance
|
ISO
|
PEMT protein promotes the reaction [AHR protein results in increased abundance of Phosphatidylcholines]
|
CTD |
PMID:29416063 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
G
|
Aifm1
|
apoptosis inducing factor, mitochondria associated 1
|
multiple interactions
|
ISO
|
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of AIFM1 protein
|
CTD |
PMID:21695227 |
|
NCBI chr X:132,528,107...132,567,237
Ensembl chr X:132,528,107...132,567,237
|
|
G
|
App
|
amyloid beta precursor protein
|
multiple interactions
|
ISO
|
[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide; [[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines; Edetic Acid inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Penicillamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Trientine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]
|
CTD |
PMID:17964426 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971
|
|
G
|
As3mt
|
arsenite methyltransferase
|
affects metabolic processing
|
ISO
|
AS3MT gene mutant form affects the metabolism of Phosphatidylcholines
|
CTD |
PMID:27591999 |
|
NCBI chr 1:255,536,879...255,569,245
Ensembl chr 1:255,537,109...255,569,249
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO
|
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of BAX protein
|
CTD |
PMID:21695227 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
ISO
|
[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of BCL2 protein
|
CTD |
PMID:21695227 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bmal1
|
basic helix-loop-helix ARNT like 1
|
increases abundance
|
ISO
|
BMAL1 gene mutant form results in increased abundance of Phosphatidylcholines
|
CTD |
PMID:27056296 |
|
NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:176,829,305...176,864,739
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions
|
ISO
|
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP3 protein
|
CTD |
PMID:21695227 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
G
|
Casp8
|
caspase 8
|
multiple interactions
|
ISO
|
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP8 protein
|
CTD |
PMID:21695227 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions
|
ISO
|
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CASP9 protein
|
CTD |
PMID:21695227 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
increases expression
|
ISO
|
Phosphatidylcholines results in increased expression of CCL2 mRNA
|
CTD |
PMID:23911798 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Ccnd1
|
cyclin D1
|
multiple interactions
|
ISO
|
[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CCND1 protein
|
CTD |
PMID:21695227 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Ccne1
|
cyclin E1
|
multiple interactions
|
ISO
|
Phosphatidylcholines promotes the reaction [rubitecan results in decreased expression of CCNE1 protein]
|
CTD |
PMID:21695227 |
|
NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822
|
|
G
|
Cdk2
|
cyclin dependent kinase 2
|
multiple interactions
|
ISO
|
[rubitecan co-treated with Phosphatidylcholines] results in decreased expression of CDK2 protein
|
CTD |
PMID:21695227 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878
|
|
G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
multiple interactions
|
ISO
|
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1A protein
|
CTD |
PMID:21695227 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
G
|
Cdkn1b
|
cyclin-dependent kinase inhibitor 1B
|
multiple interactions
|
ISO
|
[rubitecan co-treated with Phosphatidylcholines] results in increased expression of CDKN1B protein
|
CTD |
PMID:21695227 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498
|
|
G
|
Ces1d
|
carboxylesterase 1D
|
decreases expression
|
ISO
|
Phosphatidylcholines results in decreased expression of CES1D mRNA
|
CTD |
PMID:23911798 |
|
NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions
|
EXP
|
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of COL1A1 mRNA]
|
CTD |
PMID:16169303 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Crp
|
C-reactive protein
|
affects binding decreases activity
|
ISO
|
CRP protein binds to Phosphatidylcholines Phosphatidylcholines results in decreased activity of CRP protein
|
CTD |
PMID:16962105 |
|
NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514
|
|
G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
affects activity
|
ISO
|
Phosphatidylcholines affects the activity of CYP1A2 protein
|
CTD |
PMID:15966743 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
G
|
Cyp7a1
|
cytochrome P450 family 7 subfamily A member 1
|
increases activity
|
EXP
|
Phosphatidylcholines results in increased activity of CYP7A1 protein
|
CTD |
PMID:12559476 |
|
NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202
|
|
G
|
Enpp7
|
ectonucleotide pyrophosphatase/phosphodiesterase 7
|
increases hydrolysis
|
ISO
|
ENPP7 protein results in increased hydrolysis of Phosphatidylcholines
|
CTD |
PMID:12885774 |
|
NCBI chr10:104,740,763...104,745,760
Ensembl chr10:104,740,763...104,745,760
|
|
G
|
Fasn
|
fatty acid synthase
|
multiple interactions
|
ISO
|
[orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines
|
CTD |
PMID:18723500 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583
|
|
G
|
Fgf19
|
fibroblast growth factor 19
|
decreases abundance
|
ISO
|
FGF19 protein results in decreased abundance of Phosphatidylcholines
|
CTD |
PMID:29416063 |
|
NCBI chr 1:209,485,813...209,490,267
Ensembl chr 1:209,485,813...209,490,267
|
|
G
|
Gpx4
|
glutathione peroxidase 4
|
multiple interactions
|
ISO
|
GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]
|
CTD |
PMID:22433871 |
|
NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629
|
|
G
|
Hmgcr
|
3-hydroxy-3-methylglutaryl-CoA reductase
|
increases activity
|
EXP
|
Phosphatidylcholines results in increased activity of HMGCR protein
|
CTD |
PMID:12559476 |
|
NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533
|
|
G
|
Igf1
|
insulin-like growth factor 1
|
increases degradation
|
ISO
|
IGF1 protein results in increased degradation of Phosphatidylcholines
|
CTD |
PMID:2120207 |
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764
|
|
G
|
Il10
|
interleukin 10
|
increases expression
|
ISO
|
Phosphatidylcholines results in increased expression of IL10 mRNA
|
CTD |
PMID:23911798 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il1b
|
interleukin 1 beta
|
increases expression multiple interactions
|
ISO
|
Phosphatidylcholines results in increased expression of IL1B mRNA Phosphatidylcholines results in increased expression of and results in increased secretion of IL1B protein
|
CTD |
PMID:23911798 PMID:30958839 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il6
|
interleukin 6
|
increases expression
|
ISO
|
Phosphatidylcholines results in increased expression of IL6 mRNA
|
CTD |
PMID:23911798 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Lep
|
leptin
|
decreases expression
|
ISO
|
Phosphatidylcholines results in decreased expression of LEP mRNA
|
CTD |
PMID:23911798 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661
|
|
G
|
Lipc
|
lipase C, hepatic type
|
multiple interactions increases abundance
|
ISO
|
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines LIPC gene mutant form results in increased abundance of Phosphatidylcholines
|
CTD |
PMID:24777581 |
|
NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:80,390,471...80,516,285
|
|
G
|
Lipe
|
lipase E, hormone sensitive type
|
increases expression
|
ISO
|
Phosphatidylcholines results in increased expression of LIPE mRNA
|
CTD |
PMID:23911798 |
|
NCBI chr 1:90,093,433...90,112,117
Ensembl chr 1:90,093,433...90,112,117
|
|
G
|
Lipg
|
lipase G, endothelial type
|
multiple interactions increases abundance
|
ISO
|
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines LIPG gene mutant form results in increased abundance of Phosphatidylcholines
|
CTD |
PMID:24777581 |
|
NCBI chr18:70,790,077...70,811,259
Ensembl chr18:70,790,077...70,812,260
|
|
G
|
Ltf
|
lactotransferrin
|
multiple interactions
|
ISO
|
[LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
|
CTD |
PMID:16141546 |
|
NCBI chr 8:119,878,344...119,901,189
Ensembl chr 8:119,878,344...119,901,189
|
|
G
|
Mmp2
|
matrix metallopeptidase 2
|
multiple interactions
|
EXP
|
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of MMP2 mRNA]
|
CTD |
PMID:16169303 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
G
|
Nox4
|
NADPH oxidase 4
|
multiple interactions
|
ISO
|
NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]
|
CTD |
PMID:22433871 |
|
NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483
|
|
G
|
Nr0b2
|
nuclear receptor subfamily 0, group B, member 2
|
decreases abundance
|
ISO
|
NR0B2 protein results in decreased abundance of Phosphatidylcholines
|
CTD |
PMID:29416063 |
|
NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475
|
|
G
|
Nr5a2
|
nuclear receptor subfamily 5, group A, member 2
|
multiple interactions
|
ISO
|
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Phosphatidylcholines
|
CTD |
PMID:29515023 |
|
NCBI chr13:50,865,253...50,985,107
Ensembl chr13:50,867,920...50,984,938
|
|
G
|
Pafah1b1
|
platelet-activating factor acetylhydrolase 1b, regulatory subunit 1
|
multiple interactions increases secretion
|
EXP
|
PAFAH1B1 protein promotes the reaction [Terbutaline results in increased secretion of Phosphatidylcholines]; PAFAH1B1 protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased secretion of Phosphatidylcholines] PAFAH1B1 protein results in increased secretion of Phosphatidylcholines
|
CTD |
PMID:12013527 |
|
NCBI chr10:60,031,441...60,090,259
Ensembl chr10:60,032,514...60,090,196
|
|
G
|
Pafah2
|
platelet-activating factor acetylhydrolase 2
|
multiple interactions
|
ISO
|
PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]
|
CTD |
PMID:22433871 |
|
NCBI chr 5:151,890,751...151,919,896
Ensembl chr 5:151,896,832...151,919,894
|
|
G
|
Pcyt1a
|
phosphate cytidylyltransferase 1A, choline
|
multiple interactions
|
ISO
|
PCYT1A protein promotes the reaction [PLPP6 protein results in increased chemical synthesis of Phosphatidylcholines]
|
CTD |
PMID:18930839 |
|
NCBI chr11:81,818,914...81,862,623
Ensembl chr11:81,819,285...81,862,395
|
|
G
|
Pemt
|
phosphatidylethanolamine N-methyltransferase
|
multiple interactions
|
ISO
|
PEMT protein promotes the reaction [AHR protein results in increased abundance of Phosphatidylcholines]
|
CTD |
PMID:29416063 |
|
NCBI chr10:45,275,434...45,349,651
Ensembl chr10:45,275,412...45,420,037
|
|
G
|
Plin1
|
perilipin 1
|
increases expression
|
ISO
|
Phosphatidylcholines results in increased expression of PLIN1 mRNA
|
CTD |
PMID:23911798 |
|
NCBI chr 1:143,073,612...143,086,199
Ensembl chr 1:143,074,214...143,086,206
|
|
G
|
Plpp6
|
phospholipid phosphatase 6
|
multiple interactions increases chemical synthesis
|
ISO
|
PCYT1A protein promotes the reaction [PLPP6 protein results in increased chemical synthesis of Phosphatidylcholines]
|
CTD |
PMID:18930839 |
|
NCBI chr 1:236,092,642...236,095,494
Ensembl chr 1:236,090,364...236,101,554
|
|
G
|
Pnpla2
|
patatin-like phospholipase domain containing 2
|
decreases expression
|
ISO
|
Phosphatidylcholines results in decreased expression of PNPLA2 mRNA
|
CTD |
PMID:23911798 |
|
NCBI chr 1:205,982,279...205,987,361
Ensembl chr 1:205,982,258...205,987,359
|
|
G
|
Pnpla6
|
patatin-like phospholipase domain containing 6
|
affects abundance
|
ISO
|
PNPLA6 protein affects the abundance of Phosphatidylcholines
|
CTD |
PMID:36336212 |
|
NCBI chr12:6,372,284...6,401,632
Ensembl chr12:6,372,293...6,401,631
|
|
G
|
Pon2
|
paraoxonase 2
|
increases activity increases expression
|
ISO
|
Phosphatidylcholines results in increased activity of PON2 protein Phosphatidylcholines results in increased expression of PON2 mRNA
|
CTD |
PMID:12615656 |
|
NCBI chr 4:34,356,270...34,391,684
Ensembl chr 4:34,356,274...34,391,996
|
|
G
|
Pon3
|
paraoxonase 3
|
multiple interactions
|
ISO
|
Phosphatidylcholines inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin]
|
CTD |
PMID:12615656 |
|
NCBI chr 4:34,323,546...34,350,244
Ensembl chr 4:34,315,889...34,350,244
|
|
G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
increases expression
|
ISO
|
Phosphatidylcholines results in increased expression of PPARG mRNA
|
CTD |
PMID:23911798 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
G
|
Ppargc1b
|
PPARG coactivator 1 beta
|
increases abundance
|
ISO
|
PPARGC1B results in increased abundance of Phosphatidylcholines
|
CTD |
PMID:17932310 |
|
NCBI chr18:57,029,264...57,131,466
Ensembl chr18:57,029,275...57,131,466
|
|
G
|
Pten
|
phosphatase and tensin homolog
|
affects binding multiple interactions
|
ISO
|
PTEN protein binds to Phosphatidylcholines [TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to Phosphatidylcholines]
|
CTD |
PMID:15313215 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330
|
|
G
|
Retn
|
resistin
|
decreases expression
|
ISO
|
Phosphatidylcholines results in decreased expression of RETN mRNA
|
CTD |
PMID:23911798 |
|
NCBI chr12:6,508,653...6,511,115
Ensembl chr12:6,508,801...6,511,116
|
|
G
|
Sftpa1
|
surfactant protein A1
|
multiple interactions
|
ISO
|
[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]
|
CTD |
PMID:15065867 |
|
NCBI chr16:17,042,264...17,045,770
Ensembl chr16:17,042,255...17,045,769
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
EXP
|
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]
|
CTD |
PMID:16169303 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
multiple interactions
|
EXP
|
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TIMP1 mRNA]
|
CTD |
PMID:16169303 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions increases expression increases abundance
|
ISO
|
GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite] Phosphatidylcholines results in increased expression of TNF mRNA [LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Phosphatidylcholines results in increased expression of and results in increased secretion of TNF protein
|
CTD |
PMID:16141546 PMID:22433871 PMID:23911798 PMID:30958839 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
multiple interactions
|
ISO
|
Phosphatidylcholines inhibits the reaction [rubitecan results in increased expression of TP53 protein]
|
CTD |
PMID:21695227 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Txn1
|
thioredoxin 1
|
multiple interactions
|
ISO
|
[TXN protein binds to PTEN protein] inhibits the reaction [PTEN protein binds to Phosphatidylcholines]
|
CTD |
PMID:15313215 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307
|
|
|
G
|
Dek
|
DEK proto-oncogene
|
decreases chemical synthesis
|
ISO
|
DEK protein results in decreased chemical synthesis of Phosphorylcholine
|
CTD |
PMID:28558019 |
|
NCBI chr17:17,786,989...17,809,096
Ensembl chr17:17,787,139...17,810,122
|
|
G
|
Fasn
|
fatty acid synthase
|
multiple interactions
|
ISO
|
[Cerulenin results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine; [orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine
|
CTD |
PMID:18723500 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583
|
|
G
|
Hsf1
|
heat shock transcription factor 1
|
increases activity
|
ISO
|
Phosphorylcholine results in increased activity of HSF1 protein
|
CTD |
PMID:34170685 |
|
NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665
|
|
G
|
Mmp1
|
matrix metallopeptidase 1
|
multiple interactions increases expression
|
ISO
|
Genistein inhibits the reaction [Phosphorylcholine analog results in increased expression of MMP1 mRNA]; herbimycin inhibits the reaction [Phosphorylcholine analog results in increased expression of MMP1 mRNA]
|
CTD |
PMID:15878362 |
|
NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
increases expression multiple interactions
|
ISO
|
Phosphorylcholine analog results in increased expression of TIMP1 mRNA Genistein inhibits the reaction [Phosphorylcholine analog results in increased expression of TIMP1 mRNA]; herbimycin inhibits the reaction [Phosphorylcholine analog results in increased expression of TIMP1 mRNA]
|
CTD |
PMID:15878362 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases expression
|
ISO
|
Phosphorylcholine analog results in increased expression of TNF mRNA
|
CTD |
PMID:15878362 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
|
G
|
Dek
|
DEK proto-oncogene
|
decreases chemical synthesis
|
ISO
|
DEK protein results in decreased chemical synthesis of Phosphorylcholine
|
CTD |
PMID:28558019 |
|
NCBI chr17:17,786,989...17,809,096
Ensembl chr17:17,787,139...17,810,122
|
|
G
|
Fasn
|
fatty acid synthase
|
multiple interactions
|
ISO
|
[Cerulenin results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine; [orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine
|
CTD |
PMID:18723500 |
|
NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583
|
|
G
|
Hsf1
|
heat shock transcription factor 1
|
increases activity
|
ISO
|
Phosphorylcholine results in increased activity of HSF1 protein
|
CTD |
PMID:34170685 |
|
NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665
|
|
G
|
Mmp1
|
matrix metallopeptidase 1
|
multiple interactions increases expression
|
ISO
|
Genistein inhibits the reaction [Phosphorylcholine analog results in increased expression of MMP1 mRNA]; herbimycin inhibits the reaction [Phosphorylcholine analog results in increased expression of MMP1 mRNA]
|
CTD |
PMID:15878362 |
|
NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964
|
|
G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
increases expression multiple interactions
|
ISO
|
Phosphorylcholine analog results in increased expression of TIMP1 mRNA Genistein inhibits the reaction [Phosphorylcholine analog results in increased expression of TIMP1 mRNA]; herbimycin inhibits the reaction [Phosphorylcholine analog results in increased expression of TIMP1 mRNA]
|
CTD |
PMID:15878362 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases expression
|
ISO
|
Phosphorylcholine analog results in increased expression of TNF mRNA
|
CTD |
PMID:15878362 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|